



# UPLISTING MONTHLY

NOVEMBER  
2022



# Congratulations

To the 2 issuers who successfully uplisted from the OTC Markets and cross-listed from a foreign exchange to the Nasdaq this month



Organic Uplist



Cross-List



## UPLISTING SUMMARY

---

The uplisting and cross-listing market remained slow in November, with only 2 issuers listing their shares on the Nasdaq, raising a total of \$7.5 million. Both uplisting issuers are from the micro-cap space (issuers with up to \$300 million market cap). Both companies operate in the healthcare sector.

One of the newly exchange-traded companies was listed organically, meaning it did not require a simultaneous underwritten public offering in order to consummate its uplisting to the Nasdaq. The other uplisting issuer partnered with Aegis Capital Corp. to conduct a \$7,500,000 underwritten offering, cross-listing from Canada.

Overall, with Nasdaq's increased scrutiny of Micro-Cap issuers and the uncertainty in the markets, the uplisting and cross-listing market continued to decline in November.



2

TOTAL UPLISTS AND  
CROSS-LISTS IN  
NOVEMBER 2022

1

UPLIST ASSISTED BY  
INVESTMENT  
BANKERS

1


FOREIGN PRIVATE  
ISSUER CROSS-  
LISTING IN  
NOVEMBER 2022

\$7.5M

IN TOTAL, RAISED BY  
UPLISTING ISSUERS IN  
NOVEMBER




### LISTINGS




### SENIOR U.S. EXCHANGE





### UPLIST / CROSS-LIST





### WARRANT COVERAGE




### TOP PERFORMING SECTORS



### MONTH-OVER-MONTH








Both issuers uplisting and cross-listing in November are from the micro-cap space



One issuer cross-listing in November (CMND) is from Canada, also trading on the CSE and FSE



In November, one uplisting issuer partnered with an investment banker to raise capital in connection with the uplist



20 Weeks

The timeframe for Clearmind Medicine Inc. (CMND) from the initial filing of the Form F-1 to effectiveness of the registration statement and pricing on Nasdaq



Offerings	November	Year-to-Date
ThinkEquity 		5
EF Hutton 		4
MAXIM GROUP 		4
AEGIS CAPITAL CORP. 	1	5
SPARTAN CAPITAL 		2
Boustead Securities 		2
ROTH Capital Partners 		1

Dollars Raised	November	Year-to-Date
ThinkEquity 		\$54M
EF Hutton 		\$45.2M
AEGIS CAPITAL CORP. 	\$7.5M	\$29.5M
MAXIM GROUP 		\$17.6M
Boustead Securities 		\$18.2M
ROTH Capital Partners 		\$12M





## Additional Information

Lucosky Brookman's data analytics team tracks uplisting and cross-listing transactional data throughout the industry, including, but not limited to, the following data points:

### Transaction-specific data

- Capital raise amount
- Listing price
- Underwriter(s)
- Pre-listing trading platform
- Execution time
- Initial trading data
- Warrant availability
- Tradeable warrant availability
- Reverse split information
- Company professional information
- Underwriter professional information
- Company auditor
- Other various data points

### Industry-specific data

- Market trends
- Year-to-date underwriter aggregate capital raise amounts
- Year-to-date underwriter aggregate number of transactions
- Year-to-date sector information
- Average listing prices versus current market prices (including highs and lows)

If you wish to receive additional information relating to the uplisting and cross-listing market or any specific company, please contact [uplist@lucbro.com](mailto:uplist@lucbro.com).



# Lucosky Brookman LLP

Lucosky Brookman is a corporate law firm directly serving the microcap and smallcaps markets with offices in New York, New Jersey, and Philadelphia. Whether our clients engage in an uplist, cross-list, direct list, SPAC, merger, or IPO through a private placement, firm commitment underwriting, Reg A or otherwise, Lucosky Brookman is at the forefront of sophisticated OTC and senior domestic and foreign exchange listing transactions.

Lucosky Brookman is the industry leader in uplisting domestic or foreign quoted OTC companies and foreign exchange listed companies to the NASDAQ or NYSE. For micro or small cap companies to succeed in the uplist process, they need to have more than just an attorney, they need an advocate, a leader, a quarterback to proactively usher the company through the process and across the finish line. For 11 years, the attorneys at Lucosky Brookman have successfully assisted numerous companies achieve their goals by completing successful listing transactions on the NASDAQ or NYSE – many times in connection with a simultaneous financing transaction and/or a restructuring.

The Uplisting Monthly report is the most comprehensive resource dedicated to the Uplist and cross-list marketplace. It brings powerful and in-depth market data and analytics to help issuers, management teams, boards of directors, consultants and others involved in the uplisting and cross-listing process make better decisions.

**Please contact us at [uplist@lucbro.com](mailto:uplist@lucbro.com) if you would like to discuss your company's uplisting or cross-listing prospects, if you would like to better understand the uplisting and cross-listing marketplace, or if you would like to receive a comprehensive 7-8 page Uplisting Analysis of your company.**

**Lucosky Brookman LLP**

**[www.lucbro.com](http://www.lucbro.com)**

**[uplist@lucbro.com](mailto:uplist@lucbro.com)**

